医師の一分

アクセスカウンタ

zoom RSS 妊娠中の片頭痛治療薬の使用にFDAが警告/米国医療事情

<<   作成日時 : 2013/05/15 23:39   >>

ブログ気持玉 0 / トラックバック 0 / コメント 0

妊娠中の片頭痛治療薬の使用にFDAが警告/米国医療事情
 米国食品医薬品局(FDA)は、子どもの低いIQスコアにつながる可能性として、妊婦に対する片頭痛薬のバルプロ酸ナトリウムの使用に警告を発した。

-----------------------
妊娠中のバルプロ酸服用による自閉症のリスク
http://kurie.at.webry.info/201304/article_9.html

-----------------------------------------------------
FDA warns on use of certain migraine drugs during pregnancy
http://www.reuters.com/article/2013/05/06/us-migrainedrug-fda-idUSBRE9450PS20130506

Mon May 6, 2013 2:30pm EDT
(Reuters) - The U.S. Food and Drug Administration warned on the use of migraine drug valproate sodium in pregnant women as it could result in lower IQ scores in the baby.

The FDA said the results of a recent study showed that children exposed to valproate products in the womb had lower IQ at the age of six than children who were exposed to other antiepileptics.

Drugs containing valproate are used to prevent migraine headaches, treat epileptic seizures and manic episodes associated with bipolar disorder.

Abbott Laboratories' Depacon, Depakote, Depakote CP, Depakote ER and Depakene, and Noven Therapeutics LLC's Stavzor and their generics contain valproate. (r.reuters.com/nej87t)

Drugs containing valproate already carry a boxed warning for birth defects.

"Valproate medications should never be used in pregnant women for the prevention of migraine headaches because we have even more data now that shows the risks to the children outweigh any treatment benefits for this use," FDA's Director of the Division of Neurology Products, Russell Katz said.

This is the second time the FDA has warned on drugs containing valproate. In a June 2011 press release, the regulator had issued interim results of a study showing reduced cognitive functions in three-year-old children exposed to valproate.

(Reporting By Pallavi Ail in Bangalore; Editing by Roshni Menon)

----------------------------------------------------
FDA NEWS RELEASE
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm350866.htm
For Immediate Release: May 6, 2013
Media Inquiries: Sandy Walsh, 301-796-4669, sandy.walsh@fda.hhs.gov
Consumer Inquiries: 888-INFO-FDA

FDA warns pregnant women to not use certain migraine prevention medicines
Valproate products can lower IQ scores in children of mothers who used them during pregnancy

The U.S. Food and Drug Administration is alerting health care providers and patients that medications including and related to valproate sodium can cause decreased IQ scores in children whose mothers took the medication during pregnancy. Therefore, these drugs are being contraindicated for (should never be used by) pregnant women for the prevention of migraine headaches. Valproate products include valproate sodium (Depacon), divalproex sodium (Depakote, Depakote CP, and Depakote ER), valproic acid (Depakene and Stavzor), and their generics.

Valproate products have several FDA-approved uses including: prevention of migraine headaches; treatment of epilepsy (seizures); and treatment of manic episodes associated with bipolar disorder (manic-depressive disorder).

Medicines that contain valproate already have a boxed warning for fetal risk, including birth defects. The recently published Neurodevelopmental Effects of Antiepileptic Drugs (NEAD) study found further evidence of the IQ risk, leading to today’s strengthened warnings.

“Valproate medications should never be used in pregnant women for the prevention of migraine headaches because we have even more data now that show the risks to the children outweigh any treatment benefits for this use,” said Russell Katz, M.D., director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research.

For its other approved uses ? bipolar disorder and seizures ? valproate may have some value in pregnant women, but it should only be taken if other medications have not controlled the symptoms or are otherwise unacceptable. Women who can become pregnant should not use valproate unless it is essential to managing their medical condition.

Women who are pregnant, or who become pregnant while taking one of these medications, should talk to their health care professional immediately. Women should not stop taking their medication without talking to their health care professional because stopping treatment suddenly can cause serious and life-threatening medical problems for the woman or the developing fetus. Women of childbearing age taking valproate products should use effective birth control.

It is not known if there is a certain time period during pregnancy when valproate exposure can result in decreased IQ. The women in the NEAD study were exposed to antiepileptic drugs throughout their pregnancies.


The FDA’s strengthened recommendations are based on the final results of the NEAD study, which showed that children exposed to valproate products in utero had decreased IQ at age 6 when compared to children who were exposed to other antiepileptic drugs. The difference in average IQ between the children who had been exposed to valproate and the children who had been exposed to other antiepileptic drugs varied between 8 and 11 points depending on the antiepileptic drug.

In a June 2011 alert, the FDA released interim results from the NEAD study that showed reduced cognitive test scores in these valproate-exposed children at age 3, and at that time the drug labels were updated.

The FDA is working with the manufacturers to make changes to the drug labels to reflect this new information and to change the pregnancy category for prevention of migraine headaches to category X (the drug's risks outweigh the drug's benefits for this use) from category D (the drug's benefits outweigh the drug's risks for this use). Valproate products will remain category D for the other two approved indications, epilepsy and manic episodes associated with bipolar disorder.

In a drug safety communication issued today, the FDA provided a summary of the new data and recommendations for health care professionals and patients.

For additional information:
FDA Valproate Information
North American Antiepileptic Drug Pregnancy Registry
FDA Patient Network

テーマ

関連テーマ 一覧


月別リンク

ブログ気持玉

クリックして気持ちを伝えよう!
ログインしてクリックすれば、自分のブログへのリンクが付きます。
→ログインへ

トラックバック(0件)

タイトル (本文) ブログ名/日時

トラックバック用URL help


自分のブログにトラックバック記事作成(会員用) help

タイトル
本 文

コメント(0件)

内 容 ニックネーム/日時

コメントする help

ニックネーム
本 文
妊娠中の片頭痛治療薬の使用にFDAが警告/米国医療事情 医師の一分/BIGLOBEウェブリブログ
文字サイズ:       閉じる